Q2 2024 13F Holders as of 30 Jun 2024
-
Type / Class
-
Equity / Common Stock, $0.0001 par value per share
-
Shares outstanding
-
47,559,740
-
Total 13F shares
-
3,127,151
-
Share change
-
-212,515
-
Total reported value
-
$9,694,108
-
Price per share
-
$3.10
-
Number of holders
-
21
-
Value change
-
-$923,501
-
Number of buys
-
7
-
Number of sells
-
8
Institutional Holders of SAB Biotherapeutics, Inc. - Common Stock, $0.0001 par value per share (SABS) as of Q2 2024
As of 30 Jun 2024,
SAB Biotherapeutics, Inc. - Common Stock, $0.0001 par value per share (SABS) was held by
21 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
3,127,151 shares.
The largest 10 holders included
BVF INC/IL, RTW INVESTMENTS, LP, MARSHALL WACE, LLP, Sessa Capital IM, L.P., VANGUARD GROUP INC, GEODE CAPITAL MANAGEMENT, LLC, MILLENNIUM MANAGEMENT LLC, Pathstone Holdings, LLC, FIRST MANHATTAN CO. LLC., and First PREMIER Bank.
This page lists
21
institutional shareholders reporting positions in this security
for the Q2 2024 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.